The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Replacing dexamethasone in transplant-ineligible multiple myeloma: the REST study
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, comments on the REST study (NCT04939844), which aims to investigate the replacement of the corticosteroid dexamethasone in therapeutic regimens utilized for the treatment of transplant-ineligible multiple myeloma (MM), to improve patient quality of life and decrease the risk of infection. In this study, patients are treated with a combination of isatuximab, bortezomib, and lenalidomide, along with minimal dexamethasone until disease progression, with preliminary findings of this treatment approach demonstrating encouraging efficacy and a tolerable safety profile. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for lectures and educational material: Skylite DX, Schain, Novartis, Janssen-Cilag, Takeda, Pfizer, Oncopeptides, Amgen, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Celgene, GlaxoSmithKline, Abbvie
Consultancy: Janssen-Cilag, Takeda, Oncopeptides, Sanofi, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Abbvie
Research Funding: Janssen-Cilag, Oncopeptides, Sanofi, Targovax, Celgene, GlaxoSmithKline
